From Wikipedia, the free encyclopedia

Dishman Carbogen Amcis Limited
Company type Public
Industry Pharmaceuticals
Founded1983
Headquarters Ahmedabad, Gujarat, India [1]
Key people
  • Janmejay R. Vyas (Chairman & Managing Director)
  • Arpit J. Vyas (Global CFO)
  • Himani Dhotre (CEO)
ProductsBulk Drugs, Chemicals
RevenueIncrease ₹2,440 crore (US$310 million) (FY23) [2]
Decrease ₹−29 crore (US$−3.6 million) (FY23) [2]
Website www.imdcal.com

Dishman Carbogen Amcis Ltd is an Indian multinational pharmaceutical company specialized in the manufacture of active ingredients and contract development and manufacturing. Dishman employs over 1,000 people worldwide and is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).

History

The Dishman Group was founded in 1983 by Shri Janmejay R. Vyas, Managing Director of the Dishman Group. Since the beginning, the focus of the Dishman Group has been on research and development of various in-house technologies for the manufacture of quaternary ammonium compounds (quats) and active pharmaceutical ingredients. The first facility of the Dishman Group was built in 1987 in Naroda; in 1996 the company initiated its expansion at Bavla where it is currently headquartered. Through several acquisitions, [3] the Dishman Group became a global company with multiple manufacturing facilities in India, Europe and China serving pharmaceutical and biopharmaceutical companies.

Company Structure

The Dishman Carbogen Amcis Group operates in two segments: contract research services and marketable molecules such as bulk drugs, intermediates, quaternary ammonium compounds (quats), specialty chemicals and phase transfer catalysts. Dishman operates in four business units:

  • Dishman Specialty Chemicals, which manufactures phase transfer catalysts, intermediates, fine chemicals, and products for the pharmaceutical, cosmetic and related industries.
  • Dishman Vitamins and Chemicals, which manufactures vitamin D2, vitamin D3, vitamin D analogs, cholesterol and lanolin related products for pharmaceutical, cosmetic and related markets. [4]
  • Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations. [5]
  • Dishman Custom Services, which includes Dishman contract research services and the subsidiary Carbogen Amcis. [6] This business unit focuses on process research and development, API supply to support clinical trials, commercial manufacture of APIs. [7] including cytotoxic and cytostatic drugs. [8]

Locations

  • Bavla and Naroda (Ahmedabad), India: Dishman Carbogen Amcis Ltd. The Naroda and Bavla sites are operational since 1989 and 1996, respectively. These sites manufacture phase transfer catalysts, pharmaceutical intermediates, active pharmaceutical ingredients and fine chemicals.
  • Shanghai, China: Dishman Carbogen Amcis (Shanghai) Co., Ltd. The site manufactures intermediates and active pharmaceutical ingredients, including highly potent drugs.
  • Veenendaal, The Netherlands: CARBOGEN AMCIS B.V manufactures of Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and lanolin related products. The site was acquired from Solvay in 2007. [9]
  • Bubendorf, Switzerland: CARBOGEN AMCIS AG. Founded in 1987 and acquired by Dishman in 2006. [10] The site supports the development and manufacture of active pharmaceutical ingredients, highly potents drugs and complex intermediate for clinical trials and commercial purposes.
  • Aarau and Hunzenschwil Switzerland: CARBOGEN AMCIS AG. These sites operate since 1994 and 2000 and were acquired by Dishman in 2006. [10] The Aarau and Hunzenschwill sites support the development and manufacture of active pharmaceutical ingredients and complex intermediate for clinical trials and commercial purposes.
  • Vionnaz Switzerland: The facility was acquired by CARBOGEN AMCIS in 2014 and is designed to develop and manufac-ture highly potent APIs including the capability to produce highly potent warheads and linkers for antibody drug conjugates (ADCs). [11]
  • Riom, France: CARBOGEN AMCIS SAS. Founded in 1998 and acquired by Dishman in 2012. [12] The Riom site is focused on the development and production of sterile parenteral drugs for clinical trials.
  • Manchester, UK: CARBOGEN AMCIS Ltd. Operating since 1983 and acquired by Dishman in 2005. [13] The site focuses on non– GMP manufacture of complex intermediate for the pharmaceutical industry.

References

  1. ^ "DISHMAN PHARMACEUTICALS & CH (DISH:Natl India): Stock Quote & Company Profile - BusinessWeek". Investing.businessweek.com. Archived from the original on 18 January 2013. Retrieved 23 December 2011.
  2. ^ a b "Dishman Carbogen Amcis Ltd Q4 FY2023 consolidated loss at Rs. 70.72 crores". EquityBulls. 23 May 2023. Retrieved 24 June 2023.
  3. ^ "East meets West". Archived from the original on 4 March 2016. Retrieved 28 June 2012.
  4. ^ "Dishman Veenendaal". Archived from the original on 27 March 2018. Retrieved 26 July 2019.
  5. ^ http://dishmancare.com/
  6. ^ http://www.carbogen-amcis.com
  7. ^ "Archived copy" (PDF). Archived from the original (PDF) on 26 May 2012. Retrieved 28 June 2012.{{ cite web}}: CS1 maint: archived copy as title ( link)
  8. ^ http://www.pharmtech.com/pharmtech/Ingredients+Insider/CMOs-Invest-in-High-Potency-Manufacturing/ArticleStandard/Article/detail/534703 [ dead link]
  9. ^ "Archived copy" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 28 June 2012.{{ cite web}}: CS1 maint: archived copy as title ( link)
  10. ^ a b "Dishman buys Swiss pharma major Carbogen". Business Standard India. 24 August 2006.
  11. ^ CONTRACT, PHARMA. "Completes successful Swissmedic inspection at Vionnaz, Switzerland". Contract Pharma. Retrieved 10 June 2022.
  12. ^ "Carbogen Amcis Acquires Creapharm Parenterals".
  13. ^ "Indian CMO expands in Europe and Middle East".

External links

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from " https://en.wikipedia.org/?title=Dishman_Carbogen_Amcis&oldid=1161752637"